Intra-Cellular Therapies shares are trading higher after the company announced topline results from its second Phase 3 trial evaluating Lumateperone as adjunctive therapy for patients with major depressive disorder, meeting primary and key secondary endpoints.
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies shares are trading higher after the company announced positive topline results from its second Phase 3 trial evaluating Lumateperone as adjunctive therapy for major depressive disorder, meeting primary and key secondary endpoints.
June 18, 2024 | 11:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies shares are trading higher following the announcement of positive topline results from its second Phase 3 trial for Lumateperone in major depressive disorder, meeting primary and key secondary endpoints.
The positive Phase 3 trial results for Lumateperone as an adjunctive therapy for major depressive disorder are likely to boost investor confidence and drive the stock price higher in the short term. Meeting both primary and key secondary endpoints is a significant milestone, indicating strong efficacy and potential for future approval and market success.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100